269 related articles for article (PubMed ID: 16875586)
21. Immunophenotypic modulation in pediatric B lymphoblastic leukemia and its implications in MRD detection.
Thulasi Raman R; Anurekha M; Lakshman V; Balasubramaniam R; Ramya U; Revathi R
Leuk Lymphoma; 2020 Aug; 61(8):1974-1980. PubMed ID: 32281503
[TBL] [Abstract][Full Text] [Related]
22. Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.
Xiao W; Salem D; McCoy CS; Lee D; Shah NN; Stetler-Stevenson M; Yuan CM
Cytometry B Clin Cytom; 2018 May; 94(3):434-443. PubMed ID: 28888074
[TBL] [Abstract][Full Text] [Related]
23. DNA ploidy analysis as an adjunct for the detection of relapse in B-lineage acute lymphoblastic leukemia.
Kenney B; Zieske A; Rinder H; Smith B
Leuk Lymphoma; 2008 Jan; 49(1):42-8. PubMed ID: 18203010
[TBL] [Abstract][Full Text] [Related]
24. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
25. 15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges.
Chatterjee G; Dhende P; Raj S; Shetty V; Ghogale S; Deshpande N; Girase K; Patil J; Kalra A; Narula G; Dalvi K; Dhamne C; Moulik NR; Rajpal S; Patkar NV; Banavali S; Gujral S; Subramanian PG; Tembhare PR
Eur J Haematol; 2024 Jan; 112(1):122-136. PubMed ID: 37706583
[TBL] [Abstract][Full Text] [Related]
26. Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry.
Arumugam JR; Bommannan K; Radhakrishnan V; Sagar TG; Sundersingh S
Leuk Lymphoma; 2022 Mar; 63(3):644-652. PubMed ID: 34727819
[TBL] [Abstract][Full Text] [Related]
27. Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection.
Theunissen PMJ; Sedek L; De Haas V; Szczepanski T; Van Der Sluijs A; Mejstrikova E; Nováková M; Kalina T; Lecrevisse Q; Orfao A; Lankester AC; van Dongen JJM; Van Der Velden VHJ;
Br J Haematol; 2017 Jul; 178(2):257-266. PubMed ID: 28419441
[TBL] [Abstract][Full Text] [Related]
28. [The limited possibility of using a simplified approach to detect minimal residual disease by the flow cytometry technique in children with precursor B-lineage acute lymphoblastic leukemia].
Popov AM; Verzhbitskaia T; Tsaur GA; Shorikov EV; Tsvirenko SV; Savel'ev LI; Fechina LG
Klin Lab Diagn; 2011 Mar; (3):25-9. PubMed ID: 21574456
[TBL] [Abstract][Full Text] [Related]
29. Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia.
Tsitsikov E; Harris MH; Silverman LB; Sallan SE; Weinberg OK
Int J Lab Hematol; 2018 Jun; 40(3):343-351. PubMed ID: 29500862
[TBL] [Abstract][Full Text] [Related]
30. Significance of CD34/CD123 expression in detection of minimal residual disease in B-ACUTE lymphoblastic leukemia in children.
Zeidan MA; Kamal HM; El Shabrawy DA; Esh AM; Sattar RH
Blood Cells Mol Dis; 2016 Jul; 59():113-8. PubMed ID: 27282579
[TBL] [Abstract][Full Text] [Related]
31. Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring.
Langebrake C; Brinkmann I; Teigler-Schlegel A; Creutzig U; Griesinger F; Puhlmann U; Reinhardt D
Cytometry B Clin Cytom; 2005 Jan; 63(1):1-9. PubMed ID: 15624201
[TBL] [Abstract][Full Text] [Related]
32. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
[TBL] [Abstract][Full Text] [Related]
33. [Aberrant immunophenotypes in 126 patients with acute leukemia].
He JJ; Li YH; Sun XJ; Wan SG; Xu J; Su L; Tian D
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):1032-6. PubMed ID: 17956685
[TBL] [Abstract][Full Text] [Related]
34. [Immunophenotypic features of bcr/abl fusion transcript-positive B-lineage acute lymphoblast leukemia].
Li JL; Liu YR; Qin YZ; Chang Y; Fu JY; Wang H; Ruan GR; Chen SS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Apr; 11(2):142-5. PubMed ID: 12744735
[TBL] [Abstract][Full Text] [Related]
35. [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].
Zhang LP; Cheng YF; Liu GL; Lu AD; Liu YR; Wang H
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):481-5. PubMed ID: 16083543
[TBL] [Abstract][Full Text] [Related]
36. Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL.
Das N; Gupta R; Gupta SK; Bakhshi S; Seth R; Kumar C; Rai S; Singh S; Prajapati VK; Gogia A; Sahoo RK; Sharma A; Kumar L
Ann Hematol; 2021 Oct; 100(10):2487-2500. PubMed ID: 34236495
[TBL] [Abstract][Full Text] [Related]
37. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
[TBL] [Abstract][Full Text] [Related]
38. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group.
Dworzak MN; Gaipa G; Schumich A; Maglia O; Ratei R; Veltroni M; Husak Z; Basso G; Karawajew L; Gadner H; Biondi A
Cytometry B Clin Cytom; 2010 May; 78(3):147-53. PubMed ID: 20201055
[TBL] [Abstract][Full Text] [Related]
39. No prognostic significance of immunophenotypic changes at the end of remission induction therapy in children with B-lineage acute lymphoblastic leukemia.
Dai Q; Liu X; Yang H; Guo S; Wang Y; Peng L; Ye L; Chen L; Lai C; Chen Q; Zhang G; Jiang Y
Leuk Res; 2018 May; 68():57-61. PubMed ID: 29544133
[TBL] [Abstract][Full Text] [Related]
40. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia.
van Wering ER; Beishuizen A; Roeffen ET; van der Linden-Schrever BE; Verhoeven MA; Hählen K; Hooijkaas H; van Dongen JJ
Leukemia; 1995 Sep; 9(9):1523-33. PubMed ID: 7658722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]